Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of a PSA/IL-2/GM-CSF Vaccine for the Treatment of PSA-Recurrent Advanced Prostate Cancer in Hormone-Naive Patients

X
Trial Profile

A Phase 2 Study of a PSA/IL-2/GM-CSF Vaccine for the Treatment of PSA-Recurrent Advanced Prostate Cancer in Hormone-Naive Patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PSA-IL2-GM-CSF vaccine (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Oct 2018 According to an OncBioMune media release, this trial is being hosted At Urology Clinics of North Texas, a ten center 40 physician practice with 12 physicians honored with inclusion in the peer-selected The Best Doctors in America list.
    • 16 Oct 2018 According to an OncBioMune media release, the company expects to treat the first patient in early Dec 2018.
    • 16 Oct 2018 According to an Oncbiomune media release, the company has signed a work order with leading Contract Research Organization, Theradex Oncology.OncBioMune has submitted the protocol to the FDA and expects a quick review by the outside IRB. Once approved by the FDA and IRB, the clinical trial information will be submitted to clinicaltrials.gov, with the expectation that the summary of the clinical trial will soon be available for public viewing.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top